1-15 of 15
Inna Chervoneva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO3-13-05: PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer

Lubna Chaudhary, Julie Jorns, Yunguang Sun, Sailaja Kamaraju, Yee Chung Cheng, Amanda Kong, Tina Yen, Caitlin Patten, Chandler Cortina, Inna Chervoneva, Christopher Chitambar, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-13-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-13-05
Published: 02 May 2024
View article titled, Abstract PO3-13-05: PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer
Journal Articles

Abstract 5534: Needle biopsy induces pro-metastatic progression and systemic dissemination of estrogen receptor-positive breast cancer cells through the COX-2/PGE2 cascade

Hiroyasu Kameyama, Macall Leslie, Reese Simmons, Yunguang Sun, Misung Yi, Priya Dondapati, John F. Langenheim, Kar-Ming Fung, Inna Chervoneva, Hallgeir Rui, Takemi Tanaka
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5534.
https://doi.org/10.1158/1538-7445.AM2024-5534
Published: 22 March 2024
View article titled, Abstract 5534: Needle biopsy induces pro-metastatic progression and systemic dissemination of estrogen receptor-positive breast cancer cells through the COX-2/PGE<sub>2</sub> cascade
Journal Articles

Abstract P2-11-13: High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors

Lubna N. Chaudhary, Inna Chervoneva, Amy R. Peck, Yunguang Sun, Misung Yi, John F. Langenheim, Julie M. Jorns, Sailaja Kamaraju, Yee Chung Cheng, John Burfeind, Christopher R. Chitambar, Jeffrey A. Hooke, Albert J. Kovatich, Craig Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Terry Hyslop, Richard Pestell, Edith P. Mitchell, Hallgeir Rui
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-11-13.
https://doi.org/10.1158/1538-7445.SABCS22-P2-11-13
Published: 01 March 2023
View article titled, Abstract P2-11-13: High PD-L2 Protein Expression in Cancer Cells is an Independent Marker of Unfavorable Prognosis in Luminal Breast Tumors
Journal Articles

Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma

Manoela Tiago, Timothy J. Purwin, Mitchell E. Fane, Yash Chhabra, Jessica L. F. Teh, Rama Kadamb, Weijia Cai, Inna Chervoneva, Sheera Rosenbaum, Vivian Chua, Nir Hacohen, Michael A. Davies, Jessie Villanieva, Ashani T. Weeraratna, Claudia Capparelli, Julio A. Aguirre-Ghiso, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2023) 83 (2_Supplement_1): A005.
https://doi.org/10.1158/1538-7445.AGCA22-A005
Published: 15 January 2023
View article titled, Abstract A005: The aged tumor microenvironment influences tolerance to targeted therapy via NR2F1 overexpression in BRAF-mutant melanoma
Journal Articles

Abstract 40: Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma

Claudia Capparelli, Timothy J. Purwin, Manoela Tiago, Nicole Wilski, Danielle Pomante, McKenna Glasheen, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Adam E. Snook, Paolo Fortina, Xiaowei Xu, Kim Hookim, Edna Cukierman, Michael A. Davies, Meenhard Herlyn, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 40.
https://doi.org/10.1158/1538-7445.AM2021-40
Published: 01 July 2021
View article titled, Abstract 40: Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma
Journal Articles

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Claudia Capparelli, Timothy J. Purwin, Shea A. Heilman, Inna Chervoneva, Peter A. McCue, Adam C. Berger, Michael A. Davies, Jeffrey E. Gershenwald, Clemens Krepler, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (19): 5680–5693.
https://doi.org/10.1158/0008-5472.CAN-18-1001
Published: 01 October 2018
View article titled, ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma
Open the PDF for ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms

Jessica Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Ines Keibler, HooKim Kim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2304.
https://doi.org/10.1158/1538-7445.AM2018-2304
Published: 01 July 2018
View article titled, Abstract 2304: In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms
Journal Articles

Abstract 105: CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival

Edward J. Hartsough, Michele B. Weiss, Shea A. Heilman, Timothy J. Purwin, Curtis H. Kugel, Sheera R. Rosenbaum, Dan A. Erkes, Manoela Tiago, Inna Chervoneva, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 105.
https://doi.org/10.1158/1538-7445.AM2018-105
Published: 01 July 2018
View article titled, Abstract 105: CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival
Journal Articles

Abstract 2350: In vivo E2F reporting on efficacious dosing schedules of MEK plus CDK4/6 inhibition in melanoma

Jessica Teh, Neda Nikbakht, Timothy Purwin, Inna Chervoneva, Prem Patel, Michael Davies, Andrew Aplin
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2350.
https://doi.org/10.1158/1538-7445.AM2017-2350
Published: 01 July 2017
View article titled, Abstract 2350: In vivo E2F reporting on efficacious dosing schedules of MEK plus CDK4/6 inhibition in melanoma
Journal Articles

Abstract 5438: Knowledge of which miRNA isoforms are expressed in a sample can successfully discriminate amongst the 32 TCGA cancer types

Aristeidis G. Telonis, Rogan Magee, Phillipe Loher, Inna Chervoneva, Eric Londin, Isidore Rigoutsos
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5438.
https://doi.org/10.1158/1538-7445.AM2017-5438
Published: 01 July 2017
View article titled, Abstract 5438: Knowledge of which miRNA isoforms are expressed in a sample can successfully discriminate amongst the 32 TCGA cancer types
Journal Articles

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma

Jessica L.F. Teh, Timothy J. Purwin, Evan J. Greenawalt, Inna Chervoneva, Allison Goldberg, Michael A. Davies, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2016) 76 (18): 5455–5466.
https://doi.org/10.1158/0008-5472.CAN-15-3384
Published: 15 September 2016
View article titled, An <em>In Vivo</em> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma
Open the PDF for An <em>In Vivo</em> Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma

Jessica L. Teh, Timothy Purwin, Evan J. Greenawalt, Inna Chervoneva, Allison Goldberg, Michael E. Davies, Andrew Aplin
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 5199.
https://doi.org/10.1158/1538-7445.AM2016-5199
Published: 15 July 2016
View article titled, Abstract 5199: An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
Journal Articles

ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas

Claudia Capparelli, Sheera Rosenbaum, Lisa D. Berman-Booty, Amel Salhi, Nadège Gaborit, Tingting Zhan, Inna Chervoneva, Jason Roszik, Scott E. Woodman, Michael A. Davies, Yulius Y. Setiady, Iman Osman, Yosef Yarden, Andrew E. Aplin
Journal: Cancer Research
Cancer Res (2015) 75 (17): 3554–3567.
https://doi.org/10.1158/0008-5472.CAN-14-2959
Published: 31 August 2015
View article titled, ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas
Open the PDF for ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas in another window
Includes: Supplementary data
Journal Articles

Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells

Israa Salem, Lucy Aburto, Sankar Addya, Inna Chervoneva, Zhaomei Mu, Bruce Ruggeri, Massimo Cristofanilli, Sandra V. Fernandez
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3232.
https://doi.org/10.1158/1538-7445.AM2015-3232
Published: 01 August 2015
View article titled, Abstract 3232: CEP-37440, a highly selective and potent dual inhibitor of ALK and FAK1 inhibits the proliferation of inflammatory breast cancer cells
Journal Articles

Abstract 3944: Serine phosphorylation of vasodilator-stimulated phosphoprotein regulates the tumorigenic potential of colon cancer cells.

Mehboob Ali, Inna Chervoneva, Giovanni M. Pitari
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3944.
https://doi.org/10.1158/1538-7445.AM2013-3944
Published: 15 April 2013
View article titled, Abstract 3944: Serine phosphorylation of vasodilator-stimulated phosphoprotein regulates the tumorigenic potential of colon cancer cells.